Adaptimmune : Phase 1 Trial Data On Liver Cancer Show Significant Antitumor Activity

Adaptimmune Therapeutics plc (ADAP) provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. The data showed significant antitumor activity with the first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease.

The company reported a complete response in one patient, and tumor reductions with stable disease that has lasted more than 16 weeks in two patients as well as disease control in most patients at the target dose.

Bruno Sangro of Clinica Universidad de Navarra said the first results from the cell therapy trial were of great interest since they indicate obvious antitumor activity in some patients. The treatment has generally been safely applied even to cirrhotic patients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
Follow RTT